FERRARO, Diana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.195
AS - Asia 5.523
EU - Europa 5.162
SA - Sud America 998
Continente sconosciuto - Info sul continente non disponibili 210
AF - Africa 145
OC - Oceania 51
Totale 27.284
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.911
GB - Regno Unito 1.728
SG - Singapore 1.631
CN - Cina 1.258
IT - Italia 877
VN - Vietnam 776
BR - Brasile 740
HK - Hong Kong 729
DE - Germania 479
SE - Svezia 410
FI - Finlandia 389
BD - Bangladesh 301
FR - Francia 243
RU - Federazione Russa 242
UA - Ucraina 200
CA - Canada 140
TR - Turchia 133
BG - Bulgaria 129
IN - India 118
KR - Corea 112
AR - Argentina 95
ID - Indonesia 94
MX - Messico 75
ES - Italia 66
NL - Olanda 57
CZ - Repubblica Ceca 51
AU - Australia 50
PL - Polonia 50
IQ - Iraq 49
JP - Giappone 48
AT - Austria 43
ZA - Sudafrica 42
EC - Ecuador 40
AE - Emirati Arabi Uniti 35
IE - Irlanda 34
CL - Cile 31
PK - Pakistan 29
IR - Iran 27
MY - Malesia 27
CH - Svizzera 26
BE - Belgio 25
DK - Danimarca 25
CO - Colombia 24
VE - Venezuela 23
MA - Marocco 20
PH - Filippine 20
EG - Egitto 19
PY - Paraguay 17
KE - Kenya 16
LT - Lituania 16
TN - Tunisia 16
JO - Giordania 14
BZ - Belize 12
TW - Taiwan 12
UY - Uruguay 12
PE - Perù 11
SA - Arabia Saudita 11
CR - Costa Rica 10
GE - Georgia 10
PT - Portogallo 10
UZ - Uzbekistan 10
JM - Giamaica 9
NP - Nepal 9
AZ - Azerbaigian 8
DO - Repubblica Dominicana 7
HN - Honduras 7
IL - Israele 7
DZ - Algeria 6
GR - Grecia 6
HU - Ungheria 6
OM - Oman 6
QA - Qatar 6
RO - Romania 6
AL - Albania 5
KZ - Kazakistan 5
LB - Libano 5
NO - Norvegia 5
RS - Serbia 5
SI - Slovenia 5
TH - Thailandia 5
BB - Barbados 4
BO - Bolivia 4
PA - Panama 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
GA - Gabon 3
GT - Guatemala 3
HR - Croazia 3
KW - Kuwait 3
LK - Sri Lanka 3
NG - Nigeria 3
PR - Porto Rico 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
AD - Andorra 2
AM - Armenia 2
AO - Angola 2
Totale 27.029
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Ashburn 1.496
Santa Clara 1.396
Southend 1.203
Singapore 957
Woodbridge 872
Hong Kong 717
Seattle 713
Houston 703
Chandler 624
Cambridge 605
Wilmington 551
San Jose 430
Ann Arbor 354
Helsinki 326
Dearborn 317
London 301
Chicago 300
Jacksonville 292
Nyköping 284
Ho Chi Minh City 253
Los Angeles 234
Beijing 222
New York 222
Council Bluffs 218
Hanoi 183
Modena 175
Hefei 165
The Dalles 153
San Diego 143
Munich 135
Sofia 122
Princeton 120
Salt Lake City 109
Shanghai 88
Moscow 86
Buffalo 82
Seoul 81
Milan 80
Lauterbourg 78
Dallas 73
Eugene 73
Jakarta 66
São Paulo 63
Frankfurt am Main 54
Tampa 51
Elk Grove Village 50
Bremen 47
Orem 45
Phoenix 45
Rome 45
Izmir 44
Redwood City 42
North Bergen 40
Norwalk 39
Da Nang 38
Toronto 38
Warsaw 35
Boardman 34
Columbus 34
Miami 33
Rio de Janeiro 32
Málaga 30
Redondo Beach 30
Brno 29
Manchester 29
Tokyo 29
Dublin 28
Guangzhou 28
Sterling 28
Turku 28
Vienna 27
Haiphong 26
Amsterdam 25
Boston 25
Fremont 25
Lancaster 24
Melbourne 24
Chennai 23
Seongnam 23
Stockholm 23
Atlanta 22
Dulles 22
Hillsboro 22
Johannesburg 22
Kunming 22
Baghdad 21
Washington 21
Miano 20
Montreal 20
Nuremberg 20
Mexico City 19
Bar Harbor 18
Brooklyn 18
Buenos Aires 18
Edinburgh 18
Falls Church 18
Naples 18
Paris 18
Brussels 17
Totale 19.108
Salva come PNG Salva come JPEG
Nome #
Definitive childlessness in women with multiple sclerosis: a multicenter study 678
Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis 454
Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. 452
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study 424
A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord 403
Aging with HIV infection: a journey to the center of inflammAIDS, immunosenescence and neuroHIV 398
Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis 395
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient 390
Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study 378
iNKT cells in secondary progressive multiple sclerosis patients display pro-inflammatory profiles 374
A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band 370
Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis 368
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: Results from an observational study 365
False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. 363
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence 359
Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study 342
Paroxysmal ventricular tachicardia and pure right insular stroke 340
Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study 339
Acute hemichorea as unusual first multiple sclerosis presentation 336
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 330
Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome 329
Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia 328
Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients 326
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study 317
Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis 317
Methylprednisolone-induced toxic hepatitis after intravenous pulsed therapy for multiple sclerosis relapses 310
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 306
Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band‐negative patients with suspected multiple sclerosis 297
Inter-center agreement in the interpretation of oligoclonal bands 294
Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients 291
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM 289
Semiautomated segmentation of the human spine based on echoplanar images 284
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis 280
Antiepileptic drugs in the treatment of headache: Neuroprotective effect or something else? 278
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 278
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 269
Severe anemia in a patient with multiple sclerosis treated with natalizumab 268
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? 264
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS 263
Acute necrotizing encephalopathy: A relapsing case in a European adult [4] 262
Diagnostics of dysimmune peripheral neuropathies 259
Systematic assessment and characterization of chronic pain in multiple sclerosis patients 259
Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine 256
Diagnostics of anti-MAG antibody polyneuropathy 255
Abnormal Circadian Modification of Aδ-Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome 253
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis 249
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis 249
Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study 248
Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? 246
Charcot-Marie-Tooth and pain: Correlations with neurophysiological, clinical, and disability findings 242
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 241
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 239
The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate 237
Habituation to Pain in "Medication Overuse Headache": A CO2 Laser-Evoked Potential Study 236
Antiepileptic drugs in the preventive treatment of migraine in children and adolescents 236
Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study 234
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 233
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study) 230
The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study 229
Topiramate in the prevention of pediatric migraine: Literature review 218
Detection of Neurofilament Light Chain with Label-Free Electrolyte-Gated Organic Field-Effect Transistors 218
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: Acetylcholinesterase activity cannot be considered a useful biomarker 217
Left thalamomegaly in a patient with partial epilepsy 217
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 216
Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement 215
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study 212
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients 211
Multiple attack study on the available triptans in Italy versus placebo 210
Evidence of different spinal pathways for the warmth evoked potentials 208
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis 208
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 205
Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders 205
Acute hemichorea as unusual first multiple sclerosis presentation: two case reports 199
A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis 198
Antiepileptic drugs in migraine prophylaxis: state of the art 194
Cell-based assays for the detection of MOG antibodies: a comparative study 194
Treatment response score to glatiramer acetate or interferon beta-1a 191
Microglia activation: A role for mitochondrial DNA? 191
Informing MS patients on treatment options: a consensus on the process of consent taking 187
Occupational head injury and subsequent glioma 185
Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis 185
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis 183
Risk of secondary progressive multiple sclerosis: A longitudinal study 182
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia 182
Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients 176
Modulation of tregs and inkt by fingolimod in multiple sclerosis patients 176
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 172
Diagnostic features of initial demyelinating events associated with serum MOG-IgG 171
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years 171
Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus 169
Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis 157
A novel SOD1 mutation in a young ALS patient associated with slowly progressive clinical course 157
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder 150
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 141
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 140
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 138
A study of the CD45 exon 4 C77G polymorphism in a patient affected both by multiple sclerosis and pulmonary Langerhans' cell histiocytosis 135
Early clinical markers of aggressive multiple sclerosis 134
Exploring the Role of Diabetes in ALS: A Population-Based Cohort Study 129
The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies 128
Totale 25.814
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.919
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.919
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.154 0 274 249 93 40 134 107 141 252 225 403 236
2022/20231.749 198 206 146 181 198 250 21 191 193 13 102 50
2023/20241.247 33 77 60 158 229 108 147 155 30 15 63 172
2024/20254.290 151 37 47 322 911 713 198 213 499 242 382 575
2025/20268.873 525 336 704 1.013 1.399 673 967 476 842 727 681 530
2026/2027451 383 68 0 0 0 0 0 0 0 0 0 0
Totale 27.284